These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10520807)

  • 21. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting.
    Bhargava B; Kornowski R; Mehran R; Kent KM; Hong MK; Lansky AJ; Waksman R; Pichard AD; Satler LF; Leon MB
    J Am Coll Cardiol; 2000 Feb; 35(2):389-97. PubMed ID: 10676686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
    Khan MM; Ellis SG; Aguirre FV; Weisman HF; Wildermann NM; Califf RM; Topol EJ; Kleiman NS
    J Am Coll Cardiol; 1998 Jan; 31(1):31-6. PubMed ID: 9426014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
    Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schömig A;
    JAMA; 2004 Feb; 291(8):947-54. PubMed ID: 14982910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty.
    Wijpkema JS; Jessurun GA; Van Boven AJ; Versteeg DI; Hautvast RW; Tio RA
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):339-43. PubMed ID: 14571484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
    Kandzari DE; Tcheng JE; Cohen DJ; Bakhai A; Grines CL; Cox DA; Effron M; Stuckey T; Griffin JJ; Turco M; Carroll JD; Fahy M; Mehran R; Stone GW;
    Am J Cardiol; 2003 Oct; 92(7):779-84. PubMed ID: 14516875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.
    Giri S; Mitchel JF; Hirst JA; McKay RG; Azar RR; Mennett R; Waters DD; Kiernan FJ
    Am J Cardiol; 2000 Aug; 86(3):269-74. PubMed ID: 10922431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
    Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
    Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group.
    Khan MA; Liu MW; Chio FL; Yates VB; Chapman GD; Misra VK; Sweeney A; Dean LS
    Catheter Cardiovasc Interv; 2001 Jan; 52(1):40-4. PubMed ID: 11146520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
    Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention.
    Pyxaras SA; Mangiacapra F; Verhamme K; Di Serafino L; De Vroey F; Toth G; Perkan A; Salvi A; Bartunek J; De Bruyne B; Wijns W; Sinagra G; Barbato E
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):604-11. PubMed ID: 23359568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
    Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
    Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.